With Alzheimer’s disease (AD) being the most common type of dementia among the 35 million patients suffering from dementia cases worldwide, the battle to find a drug to at least slow down this disease is becoming more urgent each day. While current medicines do ease the symptoms of AD, none of them delay, stop, or reverse the cognitive and behavioral decline of AD. In recent news, a drug called bapineuzumab, that hoped to improve the cognitive and life functions of the patients participating in the trial, has failed its first of four clinical trials. The 1,100 patients in this late-stage study have mild to moderate cases of Alzheimer’s, and each has a variation of the gene, ApoE4, which increases the chances of developing AD. About half of AD patients have this gene. Bapineuzumab is an antibody based drug that targets beta-amyloid, a protein which scientists believe to be the cause of AD. The failure of this trial may be due to the high risk patients, as well as the fact that the drug is being tested too late into the disease. Jointly created by Pfizer and Johnson & Johnson, it has been announced that Johnson & Johnson will carry out the remaining three clinical trials, with one involving ApoE4 and the other two with patients without the gene. The results of these remaining trials will be presented at a neurology conference in Sweden this September. For more details and news about this study as well as Alzheimer’s disease, please visit:



Keywords: Alzheimer’s disease; bapineuzumab; ApoE4

Sources: http://www.washingtonpost.com/business/pfizer-alzheimers-disease-drug-fails-in-1-study-2nd-study-in-different-patients-continues/2012/07/23/gJQAB7K64W_story_1.html


You can follow updates on clinical trials at the Roskamp Institute Website: http://www.rfd

Wendy Liu

July 24, 2012